Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108877 | 1.00 | TP53 (0.65) | TP53LMNAHTTMEN1KMT2A | |
| SCHEMBL30399939 | 1.00 | TP53 (0.65) | TP53LMNAHTTMEN1KMT2A | |
| SCHEMBL18097894 | 0.83 | TP53 (0.68) | TP53LMNAHTTMEN1KMT2A | |
| SCHEMBL254284 | 0.83 | LMNA (0.68) | TP53LMNAHTTMEN1KMT2A | |
| SCHEMBL31045502 | 0.83 | LMNA (0.68) | TP53LMNAHTTMEN1KMT2A | |
| SCHEMBL11501929 | 0.81 | TP53 (0.48) | TP53LMNAHTTMEN1KMT2A | |
| SCHEMBL7560420 | 0.80 | TP53 (0.58) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL29700271 | 0.80 | TP53 (0.58) | TP53LMNAHTTIDO1TDO2 | |
| SCHEMBL13866426 | 0.79 | TP53 (0.63) | TP53LMNAHTTMEN1KMT2A | |
| SCHEMBL14992635 | 0.79 | TP53 (0.63) | TP53LMNAHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024153017-A1 | HETEROCYCLIC SUBSTITUTED PYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海美悦生物科技发展有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-118344343-A | Heterocyclic substituted pyrazine compound and preparation method and application thereof | 上海美悦生物科技发展有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-20240199620-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2024-06-20 | — | — | US | disclosed |
| CN-109789146-B | Chemokine receptor modulators and uses thereof | 拉普特医疗公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-3490565-B1 | AZETIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3490565-B1 | AZETIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2022-06-08 | — | — | EP | disclosed |
| US-20200239480-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200239480-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2020-07-30 | — | — | US | disclosed |
| US-10647696-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10604526-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-9790204-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2785710-B1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-2785710-B1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20160185756-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9150550-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150550-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140121195-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20140121195-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20130165423-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165423-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165423-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | TP53 2492/4885LMNA 4863/4885HTT 4109/4885 |
| US-20160185756-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | TP53 2492/4885LMNA 4863/4885HTT 4109/4885 |
| US-10604526-B2 | Chemokine receptor modulators and uses thereof | CCR4, CCR1, CCR3 | TP53 3886/4885LMNA 4831/4885HTT 4810/4885 |
| US-20200239480-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | CCR4, CCR1, CCR3 | TP53 3886/4885LMNA 4831/4885HTT 4810/4885 |
| US-20140121195-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | TP53 2492/4885LMNA 4863/4885HTT 4109/4885 |
| US-10647696-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CCR4, CCR1, CCR3 | TP53 2492/4885LMNA 4863/4885HTT 4109/4885 |
| US-20240199620-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | CCR4, CCR1, CCR3 | TP53 3886/4885LMNA 4831/4885HTT 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.